A FRET-based biosensor for measuring G alpha 13 activation in single cells by Mastop, Marieke et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/187833
 
 
 
Please be advised that this information was generated on 2018-04-11 and may be subject to
change.
RESEARCH ARTICLE
A FRET-based biosensor for measuring Gα13
activation in single cells
Marieke Mastop1, Nathalie R. Reinhard1, Cristiane R. Zuconelli2, Fenna Terwey1,
Theodorus W. J. Gadella Jr.1, Jakobus van Unen1¤, Merel J. W. Adjobo-Hermans2,
Joachim Goedhart1*
1 Swammerdam Institute for Life Sciences, Section of Molecular Cytology, van Leeuwenhoek Centre for
Advanced Microscopy, University of Amsterdam, Amsterdam, The Netherlands, 2 Department of
Biochemistry, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen,
The Netherlands
¤ Current address: Department of Biology, Institute of Cell Biology, University of Bern, Bern, Switzerland.
* j.goedhart@uva.nl
Abstract
Fo¨rster Resonance Energy Transfer (FRET) provides a way to directly observe the activa-
tion of heterotrimeric G-proteins by G-protein coupled receptors (GPCRs). To this end,
FRET based biosensors are made, employing heterotrimeric G-protein subunits tagged
with fluorescent proteins. These FRET based biosensors complement existing, indirect,
ways to observe GPCR activation. Here we report on the insertion of mTurquoise2 at sev-
eral sites in the human Gα13 subunit, aiming to develop a FRET-based Gα13 activation bio-
sensor. Three fluorescently tagged Gα13 variants were found to be functional based on i)
plasma membrane localization and ii) ability to recruit p115-RhoGEF upon activation of the
LPA2 receptor. The tagged Gα13 subunits were used as FRET donor and combined with
cp173Venus fused to the Gγ2 subunit, as the acceptor. We constructed Gα13 biosensors
by generating a single plasmid that produces Gα13-mTurquoise2, Gβ1 and cp173Venus-
Gγ2. The Gα13 activation biosensors showed a rapid and robust response when used in pri-
mary human endothelial cells that were exposed to thrombin, triggering endogenous prote-
ase activated receptors (PARs). This response was efficiently inhibited by the RGS domain
of p115-RhoGEF and from the biosensor data we inferred that this is due to GAP activity.
Finally, we demonstrated that the Gα13 sensor can be used to dissect heterotrimeric G-pro-
tein coupling efficiency in single living cells. We conclude that the Gα13 biosensor is a valu-
able tool for live-cell measurements that probe spatiotemporal aspects of Gα13 activation.
Introduction
G-protein coupled receptors (GPCRs) are members of a large family of membrane located
receptors, with around 750 genes encoding a GPCR identified in the human genome [1].
These seven transmembrane containing proteins can perceive a wide variety of signals includ-
ing light, hormones, ions and neurotransmitters [2]. GPCRs act as Guanine Exchange Factors
(GEFs) [3] for heterotrimeric G-proteins. These protein complexes are comprised of a Gα, Gβ
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and Gγ subunit. The heterotrimer is a peripheral membrane protein complex due to lipid
modification of the Gα and Gγ subunit [4].
The GEF activity is exerted on the Gα subunit, which can be converted from an inactive
GDP-bound state to an active GTP-bound state [5]. The activation of the complex results in a
conformational change and in some cases the dissociation of the Gα subunit from the Gβγ
dimer [2,6,7]. Both the activated GTP-bound Gα subunit and Gβγ dimer are capable of activat-
ing downstream effectors [2].
Almost twenty different Gα subunits can be discerned and these are grouped in four clas-
ses; Gi/o, Gs, Gq and G12/13 [2]. Throughout this manuscript we will use Gα13 to indicate
the subunit and G13 to indicate the heterotrimer, consisting of Gα13, Gβ and Gγ, the same
terminology will be used for Gq/Gαq and Gi/Gαi, respectively. Each class of Gα subunits
activates different downstream effectors [5]. The best characterized effectors of the Gα12/
Gα13 subunits are RhoGEFs that activate RhoA, e.g. LARG, PDZ-RhoGEF and p115-Rho-
GEF [8,9]. For quite some time, it was thought that GPCR activation of the Gα12/ Gα13
subunits was the predominant way to activate RhoA. This view has changed over the last
decade with the identification of RhoGEFs that can be activated by Gαq [9,10]. Nowadays,
it is clear that both Gαq and Gα12/ Gα13 can rapidly activate RhoA signaling in cells
[11,12], albeit by activating different effectors. Since the Gq class and G12/13 class both effi-
ciently activate RhoA, it has been difficult to distinguish which of these two heterotrimeric
G-protein complexes is activated when only downstream effects are measured. To further
complicate matters, GPCRs that activate G12/13 often activate Gq as well [13,14]. Yet, it is
clear that signaling through either Gq or G12/13 has different physiological effects
[13,15,16]. Therefore, it is necessary to have tools that can measure activation of the hetero-
trimeric G-protein itself.
Direct observation of heterotrimeric G-protein activation has classically been performed by
quantifying the binding of radiolabeled nucleotides [17]. This approach is labor-intensive, uses
disrupted cells and lacks temporal resolution. Moreover, this technique is generally less suit-
able for Gq, Gs and G12/13, due to their low expression levels compared to Gi [18]. On the
other hand, optical read-outs, often based on FRET and Bioluminescence Resonance Energy
Transfer (BRET) techniques are well suited to measure signaling activity with high temporal
resolution in intact cells [19,20]. Several groups have generated BRET or FRET based biosen-
sors for detecting events immediately downstream of activated GPCRs [20–24]. Optical bio-
sensors that are based on heterotrimeric G-proteins are particularly suited to report on GPCR
activation [25]. However, only a few optical biosensors for reporting activation of Gα12 or
Gα13 have been reported.
Sauliere et al. reported a BRET based biosensor for detection of activation of Gα13 acti-
vation, enabling the detection of biased-agonism via the angiotensin II type 1 receptor
(AT1R) [26]. The approach, however, lacks spatial resolution. Improved luciferases, such
as Nanoluciferase, enabled single cell BRET measurements, but longer acquisition times
are required, so temporal resolution is decreased [27]. In general, FRET-based sensors
have higher emission intensities, requiring shorter acquisition times to obtain sufficient
spatial and temporal resolution. Thus, development of a FRET based biosensor reporting
on the activation of Gα13 would be a real asset for GPCR signaling research. We have pre-
viously reported on single plasmid systems that enable the expression of a multimeric
FRET based sensor for Gαq and Gαi [28,29]. Here, we report on the development, charac-
terization and application of a single plasmid, FRET based biosensor for the activation of
Gα13.
A FRET biosensor for measuring Gα13 activation in single cells
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Results
Strategy for tagging Gα13 with a fluorescent protein
To directly measure the activation of Gα13 with high spatiotemporal resolution in living cells,
we aimed at generating a functional, fluorescent protein (FP) tagged Gα13 subunit. Gα sub-
units cannot be tagged at the N- or C-terminus since these are required for interaction with
the Gβγ subunit and the GPCR [30]. To functionally tag Gα13, the FP should be inserted in
the Gα13 sequence, as was previously done for other Gα isoforms [25,31].
Initially, we used a sequence alignment of the four classes of Gα-proteins and identified the
residues of Gαq [32] and Gαi [29] after which we had previously inserted mTurquoise2 (Fig
1B, S1 Fig). Based on sequence homology, we chose to insert mTurquoise2 after residue Q144
of human Gα13, indicated with a black rectangular box in the alignment. Upon transfection of
the plasmid encoding this variant, we observed cytoplasmic fluorescence. This localization
probably reflects incorrect folding or targeting of the Gα subunit, since well-folded and func-
tionally tagged variants are located at the plasma membrane [31,32]. Inspection of the crystal
structure (PDB ID: 1ZCB), revealed that Q144 is part of an α-helix (αB2), which is likely to be
disrupted after modification or insertion [33].
Next, we used the protein structure to select a number of residues that were nearby previous
insertion sites and next to or close to the end of an α-helix (αA, αB2 or αB1). We also took
along an insertion site (L106) that was previously used to insert a luciferase into Gα13 [26].
We used a truncated mTurquoise2, deleting the last 9 amino acids, since this worked well in
the Gi sensor [29]. The insertion sites are highlighted on the protein structure and in the
sequence alignment in Fig 1A and 1B. The different variants are numbered as Gα13.1, Gα13.2,
Gα13.3, Gα13.5 and Gα13.6 throughout the manuscript.
The plasmids encoding the different tagged variants were transfected into HeLa cells and
we observed striking differences in localization. As shown in Fig 1C, variant 1 and 6 showed
cytoplasmic localization. In contrast, strong plasma membrane labeling was observed for vari-
ant Gα13.2, Gα13.3 and to a lesser extent for Gα13.5. Since native Gα13 is expected to localize
at the plasma membrane by virtue of palmitoylation [4], we decided to continue with the opti-
mization and characterization of variants 2, 3 and 5.
Functionality of the tagged Gα13 variants
The correct localization of the tagged Gα13 variants does not necessarily reflect functionality
with respect to activity in signaling, i.e. the capacity to exchange GDP for GTP. To determine
functionality, we turned to a dynamic cell-based assay. This assay is based on the observation
that ectopic Gα13 expression is required for p115-RhoGEF relocation to the plasma mem-
brane upon GPCR stimulation [34]. To evaluate the functionality of Gα13, we co-expressed
the LPA2 receptor-P2A-mCherry [22], p115-RhoGEF, tagged with SYFP1, and different vari-
ants of Gα13, including an untagged, native variant (Fig 2, S2 Fig). Cells in which Gα13 was
not over-expressed did not show p115-RhoGEF relocation after GPCR activation (Fig 2B and
2C). However, in the presence of native Gα13, a relocation of p115-RhoGEF was noticed (Fig
2B and 2C). These findings are in agreement with previous findings and show that a functional
Gα13 is required for the recruitment of p115-RhoGEF to the plasma membrane. Next, similar
experiments were performed in the presence of Gα13 variants 2, 3 and 5, tagged with mTur-
quoise2Δ9. In all three cases a robust relocation of p115-RhoGEF was observed (Fig 2). In con-
trast, the relocation was not evident when a Gα13 variant (variant 1) was employed that did
not show efficient plasma membrane localization (Fig 2B and 2C). Hence, we observed a corre-
lation between membrane localization and functionality in the recruitment assay. Altogether,
A FRET biosensor for measuring Gα13 activation in single cells
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the results support the notion that the tagged variants 2, 3 and 5 of Gα13 can be activated by a
GPCR and are capable of recruiting p115-RhoGEF.
Evaluation of tagged Gα13 variants for measuring Gα13 activation
Having engineered several correctly localizing Gα13 variants capable of recruiting p115-Rho-
GEF, we examined whether these variants can be used to report on G13 activation. Using a
FRET-based approach (as described for Gq [32]), we monitored the interaction between the
different generated mTurquoise2-tagged Gα13 constructs and a Gβγ dimer, consisting of
untagged-Gβ and 173cpVenus- Gγ, on separate plasmids. These constructs allow acceptor
(173cpVenus)–donor (mTurquoise2) FRET ratio measurements, where G13 activation results
in a change in distance and/or orientation between the FRET pair, thereby inducing a FRET
ratio decrease.
Here we co-expressed an untagged LPA2-receptor, with one of the three tagged Gα13 vari-
ants, untagged Gβ, and tagged Gγ. Upon LPA2-receptor activation, a FRET ratio change was
observed for all three selected Gα13 variants (Fig 3A). The Gα13.2 variant showed the largest
FRET ratio change and the Gα13.5 variant the lowest (Fig 3A). Some cells expressing the
Gα13.3 variant showed a slower response (Fig 3A).
Recently, a FRET sensor for Gα13 was reported that employed a tagged Gα and a Gβ sub-
unit [35]. Therefore, we also examined if tagging the Gβ subunit instead of the Gγ subunit
yields a higher FRET ratio change for the best performing Gα13 variant. From Fig 3B it can be
inferred that tagging the Gγ subunit with the FRET acceptor results in the highest FRET ratio
change upon activation of the Gα13 via the LPA2 receptor, which is consistent with our previ-
ous observations [32].
Construction and characterization of FRET biosensors for Gα13 activity
We have previously shown for Gαq [28] and Gαi [29] activation biosensors that a single
expression plasmid ensures robust co-expression of the sensor components and simplifies the
transfection. Since all three tagged Gα13 variants are able to report on Gα13 activation using
173cpVenus-Gγ as FRET acceptor, we developed single plasmid sensors using each of the
Gα13 variants. Fig 4A shows a schematic overview of the plasmid design for a Gα13 sensor.
Analysis of CFP and YFP intensities from single cells show a better correlation for the single
plasmid system as compared to cells transfected with separate plasmids (Fig 4B).
As can be inferred from Fig 4C, the subcellular localization of the different Gα13 sensors
expressed in HeLa cells is similar. The Gα13 variants are mainly located at the plasma mem-
brane and Gγ is located to the plasma membrane and endomembranes, as published [28]. In
Hek293T cells, however, transient expression of the Gα13.2 sensor lead to very round cells that
easily detach (S3 Fig), suggesting that very high, transient expression of the sensor can result in
enhanced basal Gα13 activity.
Fig 1. Insertion of a fluorescent protein at different positions in Gα13. (A) The protein structure of human Gα13 (PDB ID: 1ZCB). The highlighted residues indicate
the amino acid preceding the inserted fluorescent protein. Successful sites for inserting mTurquoise2-Δ9 into Gα13 in pink and unsuccessful sites in orange. (B) A
partial protein sequence alignment (full alignment see S1 Fig) of different Gα classes. The highlighted residues indicate the amino acid preceding the inserted fluorescent
protein (or luciferase). In bold, the sites that were previously used to insert Rluc [26]. Insertion of mTurquoise2-Δ9 in Gα13 after residue Q144 (black) was based on
homology with previous insertions in Gαq and Gαi (black). Successful sites for inserting mTurquoise2-Δ9 (R128, A129 and R140) in pink and unsuccessful sites (L106
and L143) in orange. The numbers indicated below the alignment correspond with the Gα13 variant numbers, used throughout the manuscript. The colors under the
alignment match with the colors of the αHelices shown in (A). (C) Confocal images of the tagged Gα13 variants transiently expressed in HeLa cells. The numbers in the
left bottom corner of each picture indicate the number of cells that showed plasma membrane localization out of the total number of cells analyzed. The tagged Gα13
variants also localize to structures inside the cell, which are presumably endomembranes,. The width of the images is 76μm.
https://doi.org/10.1371/journal.pone.0193705.g001
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Next, we evaluated the performance of the sensors in Human Umbilical Vein Endothelial
cells (HUVEC). HUVECs are known to respond to thrombin, activating endogenous Protease
Activated Receptors (PARs), which results in Gα13-RhoA signaling [11,36]. We observed no
effect of ectopic sensor expression in HUVEC. When thrombin was added to HUVECs, the
Gα13.2 sensor showed the most pronounced FRET change (Fig 4D). This is in line with previ-
ously reported well-defined FRET change of the Gx13.2 sensor upon S1P stimulation in
HUVECs [11]. Based on the FRET ratio imaging data in HUVECs and HeLa, we selected the
Fig 2. Capacity of the tagged Gα13 variants to recruit p115-RhoGEF. (A) Confocal images of a representative HeLa cell expressing SYFP1-p115-RhoGEF,
Gα13.2-mTurquoise2-Δ9 and LPA2-P2A-mCherry (here only SYFP1-p115-RhoGEF is shown, for the localization of the other constructs see S2 Fig) (before (t = 0s) and
after (t = 100s) addition of 3μM LPA). The width of the pictures is 67μm. (B) The mean cytoplasmic fluorescence intensity of SYFP1-p115-RhoGEF over time. After 8s,
3μM LPA was added. All cells transiently expressed LPA2 receptor-P2A-mCherry. The number of cells imaged is p115-RhoGEF n = 5, Gα13 untagged + p115-RhoGEF
n = 15, Gα13.1 + p115-RhoGEF n = 27, Gα13.2 + p115-RhoGEF n = 28, Gα13.3 + p115-RhoGEF n = 24, Gα13.5 + p115-RhoGEF n = 20. Data have been derived from
three independent experiments. (C) Quantification of the fluorescence intensity at t = 50s for each Gα13 variant, relative to t = 0s. The dots indicate individual cells and
the error bars show 95% confidence intervals. The numbers of cells analyzed is the same as in (B).
https://doi.org/10.1371/journal.pone.0193705.g002
A FRET biosensor for measuring Gα13 activation in single cells
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Gα13.2 sensor as the Gα13 activation biosensor of choice due to its high sensitivity and robust
FRET ratio change upon Gα13 activation.
Characterization of Gα13 inhibition by a GTPase activating protein
Our data show that the Gα13.2 sensor is sensitive enough to detect G13 signaling activated by
endogenous thrombin receptors in HUVECs. We and others [11,37,38] have used a Regulator
of G-protein Signaling (RGS) domain of p115-RhoGEF as an inhibitor of G13 signaling. The
Fig 3. The ability of the tagged Gα13 variants to report on dynamic Gα13 activation via ratiometric FRET imaging. (A) Ratiometric FRET traces of HeLa cells
expressing the LPA2 Receptor (untagged), Gβ (untagged), one of the Gα13 variants (as indicated in the title of the graphs) tagged with mTurquoise2-Δ9 and Gγ tagged
with cp173Venus. The grey lines represent individual cells and the black graph represents the average of which the error bars indicate the 95% confidence intervals. LPA
was added at t = 42-50s, indicated by the arrowhead. The number of cells analyzed is: Gα13.2-mTurquoise2-Δ9 n = 20, Gα13.3-mTurquoise2-Δ9 n = 16 and
Gα13.5-mTurquoise2-Δ9 n = 11. The data from panel A are acquired on multiple days. (B) Ratiometric FRET traces of HeLa cells expressing the LPA2 Receptor
(untagged), Gα13.2-mTurquoise2-Δ9 and either Gγ tagged with cp173Venus (n = 38) (and untagged Gβ) or Gβ tagged with mVenus (n = 25) (and untagged Gγ). LPA
was added at t = 50s, indicated by the arrowhead. The data from panel B are acquired on the same day.
https://doi.org/10.1371/journal.pone.0193705.g003
A FRET biosensor for measuring Gα13 activation in single cells
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RGS domain exhibits GTPase Activating Protein (GAP) activity [39]. However, it is unclear
whether the inhibition by the RGS domain in cells is due to GAP activity or due to competitive
binding of the RGS domain and downstream effectors to Gα13. In the latter case, we would
expect a change in FRET ratio in the presence of the RGS domain. To gain insight in the mech-
anism of action, we employed the Gα13.2 sensor and co-expressed a membrane bound RGS
(Lck-mCherry-p115-RGS), which is shown to effectively inhibit RhoA activation [11].
In the presence of the RGS domain, we did not observe a FRET ratio change of the Gα13.2
sensor after adding thrombin to HUVECs (Fig 5A and 5B and S1 Movie). In the control sam-
ple (Lck-mCherry) we did observe a ratio change of the Gα13.2 sensor induced by thrombin
(Fig 5A and 5B and S2 Movie), while resting state FRET ratios were similar for both condi-
tions. The lack of a FRET response in presence of the RGS domain, reflecting suppression of
active GTP-bound Gα13, provides evidence that GAP activity is involved in the inhibitory
effect of the RGS domain. Additionally, we looked into thrombin-induced contraction of
HUVECs and show that over-expression of the RGS domain prevents cell contraction, even
leading to an overall increase in cell area (Fig 5C and S3 Movie). Together, these data show
that the RGS domain inhibits the activation of Gα13 and the consequent activation of RhoA
which effectively blocks cell contraction.
Application of the Gα13.2 biosensor in GPCR activation assays
Published data on GPCRs coupling to Gα13 is often based on indirect measures and since
downstream signaling effects overlap with the downstream signaling effects of Gq, it is difficult
to draw solid conclusions about the involvement of either subunit [14]. Our novel FRET sen-
sor enables direct observation of Gα13 activation. Therefore, we evaluated the Gαq and Gα13
responses to the stimulation of a selection of GPCRs published as coupling to Gα13
[26,34,40,41]. These experiments were performed in HeLa cells transiently expressing the cor-
responding GPCR. As a control, cells only expressing the Gα13 or Gαq sensor were stimulated,
which did not elicit a noticeable sensor response (Fig 6A). Upon LPA2 receptor (LPA2R) stim-
ulation, Gαq and Gα13 were both activated, which corresponds to published data. Of note is
that a number of cells (47 out of 60 for Gαq and 23 out of 37 for Gα13), transiently expressing
the LPA2 receptor, failed to show a Gα13 or Gαq response (Fig 6B). Upon Angiotensin II type
1 receptor (AT1R) stimulation a notable response of the Gαq sensor is observed as compared
to a minimal response of the Gα13 sensor, which is similar to the control (compare Fig 6C and
6A). The Kisspeptin receptor (KissR or GPR54) showed a clear Gαq and no Gα13 sensor
response upon stimulation (Fig 6D). Together, these results indicate that the LPA2R couples to
both Gαq and Gα13, while the AT1R and KissR are coupled to Gαq and hardly or not to
Gα13. Moreover, it shows that our novel Gα13 sensor can indeed be used to distinguish
between Gα13- and Gαq-coupled GPCR signaling.
Discussion
The combined activation of different heterotrimeric G-protein classes by a GPCR defines
which signaling networks will be activated. For one of the classes of G-proteins, G12/13, it has
Fig 4. Development and characterization of Gα13 activation FRET based biosensors. (A) Architecture of the Gα13 biosensor construct, encoding Gβ-2A-
cp173Venus-Gγ2-IRES-Gα13-mTurquoise2-Δ9, under control of the CMV promoter. (B) CFP and YFP emission was measured from individual cells expressing
the Gα13.2 sensor from a single plasmid or from cells transfected with separate plasmids that encoded Gα13.2 and cp173Venus-Gγ2. The r
2 is the correlation
coefficient. (C) Confocal images showing the localization of the Gα13 in the sensor variants (upper, cyan) and cp173Venus-Gγ2 (lower, yellow) in HeLa cells (for
Gα13.2 sensor localization in Hek293T and HUVEC see S3 Fig). The width of the images is 75μm. (D) FRET ratio traces of HUVECs expressing the different
Gα13 biosensors, stimulated with Thrombin at t = 100s (dotted lines depict 95% CI). For the corresponding YFP and CFP traces see S4 Fig. The number of cells
analyzed is: Gα13.2 sensor n = 16, Gα13.3 sensor n = 11, Gα13.5 sensor n = 16.
https://doi.org/10.1371/journal.pone.0193705.g004
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been notoriously difficult to measure its activation. Here, we report on the development, char-
acterization and application of a FRET based biosensor for Gα13 activation. This novel tool
can be used to study the activation of Gα13 by GPCRs in single living cells. We furthermore
Fig 5. Effects of the p115-RhoGEF RGS domain on Gα13.2 activity and cell morphology. (A) Normalized ratiometric traces (upper graphs) and corresponding YFP
and CFP traces (lower graphs) (dotted lines depict 95% CI) of HUVECs that were transfected with either the Gα13.2 FRET sensor and Lck-mCherry (Control, n = 11) or
the Gα13.2 FRET sensor and Lck-mCherry-RGS (+ RGS, n = 13). Cells were stimulated at t = 110s. (B) Ratiometric images of representative cells measured in (A). Cool
colors represent low YFP/CFP ratios, corresponding to emission ratios (ERs) on the right.(C) Cell area change of the cells measured in (B), visualized according to the
LUT panel on the right. Dotplots on the right represent individual measurements (± 95% CI) of corresponding cells measured in (A). Image width = 54μm.
https://doi.org/10.1371/journal.pone.0193705.g005
Fig 6. Direct observation of Gα13 and Gαq activation by different GPCRs. Normalized ratio-metric FRET traces of HeLa cells transfected with the Gq sensor (grey
line) or the G13.2 sensor (black line) (dotted lines depict 95% CI). (A) As a control, cells expressing only the Gq (n = 37) or G13.2 (n = 20) sensor were measured.
Agonists were sequentially added after 50s, 150s and 230s of imaging. (B) Ratio traces of cells transfected with an untagged LPA2 receptor next to the Gαq (n = 13 (out of
60 in total)) or the Gα13.2 (n = 14 (out of 37 in total)), stimulated at t = 50s. (C) Ratio traces of cells transfected with AngiotensinII type 1 receptor-P2A-mCherry next to
the Gαq (n = 22) or the Gα13.2 (n = 9) sensor, stimulated at t = 50s. (D) Ratio traces of cells transfected with an untagged kiss-receptor next to the Gαq (n = 13) or the
Gα13.2 (n = 30) sensor, stimulated at t = 50s (indicated with the arrowhead).
https://doi.org/10.1371/journal.pone.0193705.g006
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show that the G13 sensor is sensitive enough to report on the activation of an endogenous
receptor in human primary cells (HUVECs).
Thus far, the tools available to study the activation of Gα13 in single living cells have been
limited. BRET-based strategies have been used to study activation of the G12 class. To this
end, Renilla reniformis luciferase (Rluc) was inserted in Gα13 after residue Ile 108 [42] or Leu
106 [26]. However, we find that insertion of mTurquoise2 after residue Leu 106 (Gα13.1) does
not result in a functionally tagged subunit, possibly because Leu106 is part of an α-helix.
Three of the five evaluated mTurquoise2 insertion sites resulted in plasma membrane local-
ized, tagged Gα13, which were able to recruit p115-RhoGEF to the plasma membrane. The
cytoplasmic-localized, tagged Gα13.1 variant was not able to recruit p115-RhoGEF, indicating
that plasma membrane localization is required for functionality. Since all functional Gα13 var-
iants could report on G13 activation as determined by FRET ratio-imaging, we developed sin-
gle plasmid sensors for these three variants. In HeLa cells the localization is as expected, Gα13
at the plasma membrane and Gγ at the plasma membrane and endomembranes. The Gα13
activation biosensors were expressed in HUVECs and could report on G13 activation via
endogenous Protease Activated Receptors (PARs). The Gα13.2 sensor is the best performing
Gα13 biosensor, based on its sensitivity and magnitude of the FRET ratio change upon activa-
tion. Further improvement of the sensors might be achieved by varying FRET pairs [43] or
changing their relative orientation by circular permutation [44].
While our manuscript was in preparation, another mTurquoise2 tagged Gα13 variant was
reported [35]. In that study, the fluorescent protein was inserted after residue 127 of Gα13,
closely resembling our Gα13.2 variant, and it showed plasma membrane localization. More-
over, Bodmann et al. observed a FRET change when an YFP tagged Gα13 variant was used in
combination with a CFP tagged Gβ subunit to report on the activation of the thromboxane A2
receptor [35]. The independent observation of a FRET change using a similar tagged Gα13
variant, supports our notion that the G13.2 FRET based biosensor is a valuable tool for study-
ing the activation of Gα13.
An advantage of our FRET sensor is that a higher ratio change is detected than for the sen-
sor reported by Bodmann et al. 2017. While they detected a maximal FRET ratio change of
10%, we could reach a FRET ratio change of up to 25% (Fig 3). This might be due to using a
tagged Gβ instead of Gγ subunit, since we also observe a lower FRET ratio change when a
tagged Gβ is employed (Fig 3B). It is remarkable that Bodmann et al. detect a FRET increase
upon Gα13 stimulation (increased YFP, decreased CFP intensity) whereas we detect a FRET
decrease upon Gα13 stimulation (Fig 3B). All of the G-protein sensors reported by us (Gαq,
Gαi1,2,3 and Gα13) show a FRET decrease upon activation under all conditions tested thus far
[11,29,32], consistent with a dissociation of Gα and Gβγ subunits. Moreover, Gα13 subunits,
tagged at different sites (Gα13.2, Gα13.3 and Gα13.5) all show a FRET decrease (Fig 3). One
notable difference is that we use a donor tagged Gα13 and Bodmann et al. use an acceptor
(YFP) tagged Gα13. However, it is unclear how this difference would lead to opposite changes
in FRET upon activation and as such, we do not have a solid explanation for the differences in
FRET change observed by Bodmann et al. [35] and in this study.
An advantage of the sensor that we constructed, is that it enables the simultaneous produc-
tion of the three proteins that comprise the heterotrimer from a single plasmid and that the
donor and acceptor are present at a well-defined stoichiometry [28]. This is evident from the
better correlation between CFP and YFP emission intensities as compared to transfection of
separate plasmids (Fig 4B). Moreover, the single plasmid system simplifies the distribution
and application of the sensor. Especially in primary cells, such as HUVECs, it is more compli-
cated to obtain simultaneous protein expression from multiple plasmids, whereas transient
expression of the single sensor plasmid in HUVECs was efficient.
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The RGS domain of p115-RhoGEF effectively inhibits GPCR-Gα12/13 mediated RhoA
activation in endothelial cells [11] and cell contraction as shown in Fig 5C. Under these condi-
tions, the Gα13.2 sensor did not display a FRET ratio change, reflecting a lack of activation.
The absence of a FRET change is consistent with the idea that the GAP activity of the RGS
domain shuts down Gα13 activity [39].
Applying the Gα13.2 sensor in HeLa cells, we showed that both Gα13 and Gαq are activated
via the LPA2 receptor. In contrast, the Kiss receptor and the AT1 receptor elicited predomi-
nantly a Gαq sensor response. From our data it is not possible to judge whether the minor
response of Gα13 upon AT1 receptor activation is biologically relevant. The GPCRs analyzed
in this study, were reported as coupling to Gα13 and/or Gαq in other studies[26,34,40,41]. Of
note, transient expression of the LPA2 receptor shows several non-responders in terms of Gαq
or Gα13 activity. This could be explained by insufficient levels of receptor to achieve detectable
activation.
Strikingly, the Kiss receptor did not activate the Gα13 biosensor, indicating that aspecific,
promiscuous coupling of a GPCR to an ectopically expressed G-protein biosensor is not
detected. Conversely, we previously observed that HUVEC treated with S1P do show Gα13
activation, but no Gαq activation [11]. Together, these observations suggest that our FRET
based biosensor toolkit provides a way to determine GPCR coupling selectivity towards het-
erotrimeric G-proteins in living cells. It would be advisable to complement such studies with
more downstream read-outs to verify the possible perturbation by the ectopically expressed G-
protein sensors.
In summary, the results obtained in this study point out that the Gα13.2 biosensor is a sen-
sitive Gα13 activation sensor for live cell imaging, that is suitable for application in primary
cells and able to detect endogenous GPCR activation.
Material & methods
Cloning/plasmid construction
mTurquoise2-Δ9 was inserted in the Gα13 sequence using a previously reported strategy [29].
A PCR was performed on the mTurquoise2 sequence to truncate it and flank it with AgeI sites
using primers Fw 5’-ATACCGGTTCTATGGTGAGCAAGGGCG-3’ and Rv 5’-TAACCGGT
GATCCCGGCGGC -3’. To determine at which positions we wanted to insert mTurquoise2 in
Gα13, we used Pymol to look at the structure of Gα13 and we used ClustalW to make an align-
ment of multiple Gα classes. A whole-vector PCR was performed on a pcDNA vector encoding
human Gα13 (ordered from cDNA.org) to introduce an AgeI restriction site at the spot where
we wanted to insert mTurquoise2, using primers Fw 5’-ATACCGGTCATATTCCCTGGGGAGA
CAAC-3’ and Rv 5’- ATACCGGTAAGCTTCTCTCGAGCATCAAC-3’for Gα13.1, primers
Fw 5’-ATACCGGTGCCCCCATGGCAGCCC-3’ and Rv 5’-ATACCGGTCCGGGTATCAAACG
ACATCATCTTATC-3’ for Gα13.2, primers Fw 5’-ATACCGGTCCCATGGCAGCCCAAGG-
3’ and Rv 5’-ATACCGGTGGCCCGGGTATCAAACGAC-3’ for Gα13.3, primers Fw 5’-ATA
CCGGTGTTTTCTTACAATATCTTCCTGCTATAAGA-3’and Rv 5’-ATACCGGTCCTTGTT
TCCACCATTCCTTG-3’ for Gα13.5 and primers Fw 5’-ATCCGGTCAATATCTTCCTGCTAT
AAGAGCA-3’ and Rv 5’-ATACCGGTTAAGAAAACCCTTGTTTCCACC-3’ for Gα13.6. The
Gα13 pcDNA vector including AgeI site and the mTq2 PCR product were cut with AgeI and
ligated, resulting in mTurquoise2 tagged Gα13. Of note, the cloning of variant Gα13.4, with an
insertion of mTurquoise2-Δ9 after T139, failed.
We used GFP-p115-RhoGEF (a kind gift of Keith Burridge, UNC, Chapel Hill, USA) as a
template to amplify p115-RhoGEF with the primers Fw 5’- AACAGATCTCTTGGTACCGAG
CTCGGATC-3’ and Rv 5’-AGCGTCGACTCAAGTGCAGCCAGGCTG-3’. The PCR product,
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flanked with the restriction sites BglII and SalI, was used to clone p115-RhoGEF into a clon-
tech-style C1 vector, generating mVenus-p115-RhoGEF.
The untagged LPA2 receptor was ordered from cDNA.org. To create the clontech-style N1
LPA2 receptor-P2A-mCherry construct, a PCR was performed using primers Fw 5’- AGG
TCTATATAAGCAGAGC-3’and Rv 5’- TATGTCGACTTGGGTGGAGTCATCAGTG-3’. The
N1-P2A-mCherry construct, described previously [22] and the LPA2 receptor PCR product
were digested with EcoRI and SalI and ligation resulted in the LPA2 receptor-P2A-mCherry
construct.
The G13 single plasmid sensor variants were constructed as descripted previously by over-
lap-extension PCR [29,45]. The first PCRs were performed on the previously published Gαq
sensor [28] using primerA Fw 5’-GAAGTTTTTCTGTGCCATCC-3’ and primerB Rv 5’-GT
CCGCCATATTATCATCGTGTTTTTCAAAG-3’ and on the mTurquoise2 tagged Gα13 vari-
ants using primerC Fw 5’-ACGATGATAATATGGCGGACTTCCTGC-3’ and primerD Rv
5’-ATCAGCGGGTTTAAACG-3’. The second PCR was performed on a mix of both PCR
products using primerA and primerD. This second PCR product and the Gαq sensor were
digested with SacI and XbaI and the PCR product was ligated into the sensor, resulting in a
G13 single plasmid sensor.
Lck-mCherry-p115-RhoGEF-RGS was constructed as described before [11]. The
p115-RhoGEF-RGS domain (amino acid 1–252) was PCR amplified using Fw 5’-GAGATCA
GATCTATGGAAGACTTCGCCCGAG-3’ and Rv 5’-GAGATCGAATTCTTAGTTCCCCATCAC
CTTTTTC-3’. The PCR product and clontech-style C1 Lck-mCherry vector were digested with
BglII and EcoRI and ligation resulted in a clontech-style C1 vector encoding Lck-mCherry-p115-
RhoGEF-RGS.
The untagged Kiss receptor was purchased from www.cDNA.org.
The rAT1aR-mVenus was a kind gift from Peter Va´rnai (Semmelweis University, Hun-
gary). The coding sequence of AT1R was inserted into mCherry-N1 with a P2A peptide to
obtain AT1R-P2A-mCherry.
Cell culture and sample preparation
HeLa cells (CCL-2, American Tissue Culture Collection; Manassas,VA, USA) were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) (Gibco, cat# 61965–059) supplemented with
10% fetal bovine serum (Invitrogen, cat# 10270–106), 100U/ml penicillin and 100 μg/ml strep-
tomycin at 37 ˚C in 7% CO2. For microscopy experiments, cells were grown on 24mm Ø round
coverslips, 0.13–0.16 mm thick (Menzel, cat# 360208) to 50% confluency and transfected with
500ng plasmid DNA, 1 μL Lipofectamin 2000 (Invitrogen, cat# 11668–019) or 4.5 μl PEI (1 mg/
ml) in water (pH 7.3) and 100 μl OptiMEM (Gibco, cat# 31985–047) per 35mm Ø dish holding
a 24mm Ø coverslip. One day after transfection the coverslip was mounted in a cell chamber
(Attofluor, Invitrogen). Microscopy medium (20 mM HEPES (pH = 7.4), 137 mM NaCL, 5.4
mM KCl, 1.8 mM CaCl2, 0.8 mM MgCl2 and 20 mM glucose) was added to the coverslip in the
cell chamber. The ratiometric FRET experiments were performed at 37 ˚C.
Primary HUVECs, acquired from Lonza (Verviers, Belgium) were seeded on fibronectin
(FN)-coated culture flasks. HUVECs, grown in EGM-2 medium, supplemented with single-
quots (Lonza) at 37 ˚C in 5% CO2. For microscopy experiments HUVECs were transfected at
passage #4 or #5 with a Neon transfection system (MPK5000, Invitrogen) and Neon transfec-
tion kit (Invitrogen) and grown on FN-coated 24mm Ø round coverslips, 0.13–0.16 mm thick
(Menzel, cat# 360208). Per transfection, 2μg plasmid DNA was used and a single pulse was
generated at 1300 Volt for 30 ms. [11]. The ratiometric FRET experiments were performed at
37 ˚C in EGM-2 medium and in 5% CO2.
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Confocal microscopy
To obtain confocal images of live HeLa cells transiently expressing either a tagged Gα13 vari-
ant or G13 single plasmid sensor, a Nikon A1 confocal microscope, equipped with a 60x oil
immersion objective (Plan Apochromat VC, NA 1.4), was used. The pinhole size was set to 1
Airy unit. To check the localization of tagged Gα13 variants, samples were excited with a
457nm laser line, a 457/514 dichroic mirror was used and the emission was filtered through a
482/35BP filter. To check the localization of the G13 single plasmid sensor constructs, samples
were excited with a 440nm (CFP) and a 514nm (YFP) laser line, a 457/514 dichroic mirror was
used and the emission was filtered through a 482/35BP (CFP) or 540/30BP (YFP), respectively.
Images were acquired with sequential line scanning modus, to avoid bleedthrough.
p115-RhoGEF recruitment assay
For the p115-RhoGEF recruitment assay, HeLa cells were cultivated in RPMI medium supple-
mented with 10% fetal calf serum and L-Glutamine (2 mM) (PAN Biotech GmbH, Aidenbach,
Germany) and kept at 7˚C in a 5% CO2 atmosphere. Cells were harvested, and 50.000 cells/
well were seeded in eight-well μ-slides (Ibidi). After 24 hours, cells were transiently transfected
with 0.25 μg of the LPA2receptor-P2A-mCherry, the SYFP1-p115-RhoGEF and the Gα13 vari-
ants tagged with mTurquoise2 (Gα13.1, Gα13.2, Gα13.3, Gα13.5). Transfection of HeLa cells
was performed using Lipofectamine 3000 and Plus Reagent, according to the manufacturer’s
instructions (Invitrogen). Twenty-four hours after transfection, the growth medium was
replaced by RPMI phenol red-free medium and measurements were performed after a total
incubation time of 48h. Throughout the measurements, cells were kept at 37˚C. Cells were
stimulated with Oleoyl-L-α-lysophosphatidic acid (10 μM, Sigma) at the indicated time point.
Confocal images were taken with a Leica TCS SP5 laser scanning confocal microscope (Leica
Microsystems, Mannheim, Germany) equipped with an HCX PL APO 63×, N.A. 1.2, water
immersion lens. mTurquoise2 was excited at 458 nm and emission was detected between 465–
500 nm; SYFP1 was excited at 514 nm and emission was detected between 520–550 nm;
mCherry was excited at 561 nm and emission was detected between 600–670 nm. To avoid
bleedthrough, images were acquired in the sequential line scanning modus. Image analysis was
performed with Fiji.
Widefield microscopy
Ratiometric FRET imaging HeLa cells. Ratiometric FRET experiments were performed
on a wide-field fluorescence microscope (Axiovert 200 M; Carl Zeiss GmbH)[32] equipped with
a xenon arc lamp with monochromator (Cairn Research, Faversham, Kent, UK) and Metamorph
6.1 software, for 240s or 288s (controls in Fig 6A) and with a time interval of 2s. The fluorescence
intensity of the donor and acceptor were recorded with an exposure time of 200ms per image
using a 40x objective (oil-immersion Plan-Neo- fluor 40×/1.30; Carl Zeiss GmbH). HeLa cells
were used, expressing cp173Venus-Gγ (or untagged Gγ in Fig 3B), untagged Gβ (or mVenus
tagged Gβ in Fig 3B) and one of the mTurquoise2 tagged Gα13 variants from multiple plasmids
or expressing the single plasmid Gq-sensor or one of the G13 sensor variants. A GPCR is
expressed from a separate plasmid, which was either untagged LPA2 receptor, untagged Kiss
receptor or AngiotensinII type 1 receptor-P2A-mCherry. Fluorophores were excited with 420
nm light (slit width 30 nm), mTq2 emission was detected with the BP470/30 filter, YFP emission
was detected with the BP535/30 filter and RFP emission was detected with a BP620/60 filter by
turning the filter wheel. After 50 s HeLa cells (unless stated otherwise) were stimulated with
either a final concentration of 3μM LPA (Sigma), 100nM Kiss-1 (112–121) Amide (Phoenix
pharmaceuticals) or 10μM angiotensin (Sigma). The curves were normalized to the average
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intensity of the first 5 frames that were recorded. ImageJ was used to perform a background cor-
rection and calculation of mean intensity of each cell for each time point. Cells that did not show
a visible response were not used for the analysis. The total number of cells imaged and the num-
ber of cells analyzed (“the responders”) are indicated in the figure legends.
Ratiometric FRET imaging HUVECs. To perform ratiometric FRET experiments on
HUVECs we used the same microscopy equipment and filter settings as were used to perform
ratiometric FRET imaging of HeLa cells, however there are some differences in the way the
data is recorded. The HUVECs are imaged for 1230s with a time interval of 10s and the imag-
ing is performed at 37 ˚C in EGM-2 medium and in 5% CO2. After 110s, HUVECs were stim-
ulated with a final concentration of 1U/ml thrombin (Haematologic Technologies). The image
processing procedure that was used to display the change in cell area during live cell micros-
copy of HUVECs is described elsewhere [11]). In order to show the FRET ratio in images of
cells, imageJ was used. We first converted the CFP and the YFP stack to 32-bit type and cor-
rected for background signal. Then the stacks were divided to obtain a YFP/CFP stack. We
used the CFP stack to make a binary mask and multiplied this mask with the YFP/CFP stack.
Finally, we applied a smooth filter to reduce noise and used the lookup table (LUT) to visualize
changes in FRET ratio.
Supporting information
S1 Fig. Full amino acid alignment of four classes of human Gα subunits of heterotrimeric
G-proteins. Note that the amino acid sequence of Gαs is that of the short isoform. The
highlighted residues indicate the amino acid preceding the inserted fluorescent protein (or
luciferase). In bold, the sites that were previously used to insert Rluc (Saulière et al., 2012).
Insertion of mTurquoise2-Δ9 in Gα13 after residue Q144 (black) was based on homology with
previous insertions in Gαq and Gαi (black). Successful sites for inserting mTurquoise2-Δ9
(R128, A129 and R140) in pink and unsuccessful sites (L106 and L143) in orange.
(PNG)
S2 Fig. Confocal images of HeLa cells expressing both the Gα13.2-mTurquoise2 (left) and
LPA2-p2A-mCherry (right) used in p115-RhoGEF recruitment assay (Fig 2). The width of
the images is 67μm.
(PNG)
S3 Fig. Confocal microscopy images of Hek293T cells (left) or widefield microscopy images
of HUVECs, both expressing the G13.2 sensor. The upper images show Gα13.2 localization
and the lower images show Gγ localization. Hek293T cells were excited with 457nm (CFP) and
514nm (YFP) light and respectively, a 482/35BP and 540/30BP were used for detection of
emission light. The width of the images is 70μm. HUVEC cells were excited with 420nm (CFP)
and 490nm (YFP) light and respectively, a 470/30BP and 535/30BP were used for detection of
emission light.
(PNG)
S4 Fig. The CFP and YFP traces of HUVECs expressing the different G13 biosensors, stim-
ulated with 1 U/ml thrombin at t = 100s (dotted lines depict 95% CI). The number of cells
analyzed is: G13.2 sensor n = 16, G13.3 sensor n = 11, G13.5 sensor n = 16.
(PNG)
S1 Movie. Dynamics of Gα13 activation in the presence of the Lck-mCherry-RGS, related
to Fig 5B.
(AVI)
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S2 Movie. Dynamics of Gα13 activation in the presence of the Lck-mCherry (control),
related to Fig 5B.
(AVI)
S3 Movie. Analysis of the endothelial cell area changes induced by thrombin, related to Fig
5C.
(AVI)
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